Duke-NUS Medical School and Lion TCR Ink Exclusive IP Licensing Agreement for Immunosuppressive Drug-Resistant Anti-Cancer T-Cells

In a move that will bring hope to liver transplant patients around the world, Lion TCR, a Singapore biotechnology company, has signed an exclusive worldwide licensing agreement with Duke-NUS Medical School to develop an innovative method of using gene-edited T cells to treat recurring cancers in the donated organ.